false
0001833498
0001833498
2024-02-07
2024-02-07
0001833498
MDAI:CommonStockParValue0.0001PerShareMember
2024-02-07
2024-02-07
0001833498
MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2024-02-07
2024-02-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 7, 2024
SPECTRAL
AI, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-40058 |
|
85-3987148 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
2515 McKinney Avenue, Suite 1000
Dallas, Texas |
|
75201 |
(Address of principal executive offices) |
|
(Zip Code) |
(972) 499-4934
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communication pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencements communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
MDAI |
|
The Nasdaq Stock Market LLC |
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $11.50 per share |
|
MDAIW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers |
The board of directors (the
“Board”) of Spectral AI, Inc., a Delaware corporation (the “Company”) appointed Dr. J. Michael DiMaio
to serve as director on the Company’s Board, effective immediately. Dr. Michael DiMaio is one of the Company’s founders and
previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020. In 2020, he
exited his positions with the Company and amicably resolved a dispute that had arisen at that time. He is the Chief of Staff and a practicing
board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest cardiovascular
programs in the United States. Currently the hospitals that he oversees are rated with the highest quality scores by the Society of Thoracic
Surgeons, Society of Vascular Surgery, and the American College of Cardiology. He supervises more than 650 physicians across six facilities
that perform approximately 25,000 cardiovascular procedures annually.
Dr. DiMaio earned his medical
degree from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke
University Medical Center and performed research under an NIH-sponsored grant. He has been elected or served as a member on many distinguished
medical organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American
Association of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation,
American Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.
He has authored nearly
500 peer-reviewed publications and abstracts and directs a research group that has produced over 1000 publications in medical
journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation. Dr. Michael DiMaio has served as an
editorial board member or reviewer for some the most prestigious medical journals in the world and has served as a grant reviewer
for the National Institutes of Health (NIH), the American Heart Association, and the U.S. Department of Defense in an addition to
serving on international medical guideline committees.
In clinical trials, he has been the principal investigator for numerous
medical drugs and devices that have received FDA approval and commercialization. He has been awarded over $150 million funding from the
NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense, the Department of Health and Human
Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees more than 120 clinical trials at
the Baylor Scott & White Research Institute and serves as Chairman of the Cardiovascular Research Review Committee for the health
care system.
Item 7.01. |
Regulation FD Disclosure. |
On February 12, 2024, the
Company issued a press release announcing the appointment of Dr. J. Michael DiMaio as a director on the Company’s Board, a copy
of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item
7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 12, 2024
|
SPECTRAL AI, INC. |
|
|
|
By: |
/s/ Wensheng Fan |
|
Name: |
Wensheng Fan |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
Spectral AI Appoints Dr. J. Michael DiMaio to
Board of Directors
The Company’s two largest stockholders
holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days
DALLAS, TX - February 12, 2024 -
Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company
focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today
announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024. Dr. DiMaio joins the Board as
a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
Dr. Michael DiMaio is one of the Company’s
founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020. In
2020, he exited his positions with the Company and amicably resolved a dispute that had arisen at that time. He is the Chief of Staff
and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest
cardiovascular programs in the United States. Currently the hospitals that he oversees are rated with the highest quality scores by the
Society of Thoracic Surgeons, Society of Vascular Surgery, and the American College of Cardiology. He supervises more than 650 physicians
across six facilities that perform approximately 25,000 cardiovascular procedures annually.
Dr. DiMaio earned his medical degree
from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke University
Medical Center and performed research under an NIH-sponsored grant. He has been elected or served as a member on many distinguished medical
organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American Association
of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation, American
Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.
He
has authored nearly 500 peer-reviewed publications and abstracts and directs a research group that has produced over 1000
publications in medical journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation.
Dr. Michael DiMaio has served as an editorial board member or reviewer for some the most prestigious medical journals in the world
and has served as a grant reviewer for the National Institutes of Health (NIH), the American Heart Association, and the U.S.
Department of Defense in an addition to serving on international medical guideline committees.
In clinical trials, he has been the
principal investigator for numerous medical drugs and devices that have received FDA approval and commercialization. He has been awarded
over $150 million funding from the NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense,
the Department of Health and Human Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees
more than 120 clinical trials at the Baylor Scott & White Research Institute and serves as Chairman of the Cardiovascular Research
Review Committee for the health care system.
“I
am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors,”
said Richard Cotton, Chairman of the Board of Directors. “Dr. DiMaio’s deep knowledge and application of innovative
medical device technologies, decades of direct patient care, and experiences within some of the United States’ preeminent medical
systems and current leadership make him uniquely qualified to support the planned commercialization and ongoing development of our DeepViewÔ
System.”
“I have spent a great deal of
my career developing technologies that improve patient outcomes while delivering tangible value across the healthcare spectrum and founded
this company with the intent to fill the unmet clinical need for a decision-assist device to improve wound care management,” said
Dr. DiMaio. “I believe that the Company’s AI-driven wound imaging and assessment technology platform is poised to deliver
on those objectives, and I am very pleased to be in a position to help advance this exciting technology towards commercialization of current
and future indication developments.”
The Company also announced that Dr.
DiMaio and Erich Spangenberg, who together hold approximately 45% of the Company’s outstanding shares, have each agreed to an additional
six-month extension of the current lock-up of their outstanding shares pursuant to the Registration Rights/Lock-Up Agreement entered into
by each of them in connection with the Company’s business combination transaction in September 2023.
About Spectral AI
Spectral AI, Inc. is
a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with
initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of
wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is
a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior
to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard
of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value
care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made
in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United
States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives,
initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,”
“anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,”
“may,” “will,” “should,” “future,” “propose” and variations of these words
or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking
statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties,
assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes
to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance
on any forward-looking statements.
Investors should carefully
consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s
filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address
other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking
statements.
Contacts
Investors |
|
Equity Group |
|
Devin Sullivan |
Conor Rodriguez |
Managing Director |
Analyst |
dsullivan@equityny.com |
crodriguez@equityny.com |
Media
Russo
Partners
David Schull
(858) 717-2310
david.schull@russopartnersllc.com
3
v3.24.0.1
Cover
|
Feb. 07, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Feb. 07, 2024
|
Entity File Number |
001-40058
|
Entity Registrant Name |
SPECTRAL
AI, INC.
|
Entity Central Index Key |
0001833498
|
Entity Tax Identification Number |
85-3987148
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2515 McKinney Avenue
|
Entity Address, Address Line Two |
Suite 1000
|
Entity Address, City or Town |
Dallas
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
75201
|
City Area Code |
972)
|
Local Phone Number |
499-4934
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
MDAI
|
Security Exchange Name |
NASDAQ
|
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $11.50 per share |
|
Title of 12(b) Security |
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $11.50 per share
|
Trading Symbol |
MDAIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=MDAI_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=MDAI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Rosecliff Acquisition Co... (NASDAQ:RCLFU)
Historical Stock Chart
From May 2024 to Jun 2024
Rosecliff Acquisition Co... (NASDAQ:RCLFU)
Historical Stock Chart
From Jun 2023 to Jun 2024